


Patient Enrollment Form for TASCENSO ODT® (fingolimod) Orally Disintegrating Tablets

Phone: +1 (888) 360-8482 FAX: +1 (888) 385-8482



 \rightarrow

To Enroll, Fax this form:

+ 1 (888) 385-8482

Or email: hello@cyclevita.life

All required fields are purple and noted with an asterisk*

	Patient Last Name*			Patient First Name*				
	Date of Birth*	Gender*	Male	Female	Other			
NO	Parent/Guardian Name (if patient is a minor) / Car	egiver Name	Relationsh	ip to Patient			rney/Medical Proxy	
E						Yes	No	
W	Street Address*					Suite/Floor/Apt #		
OR								
PATIENT INFORMATION	City*					State*	Zip code*	
	Preferred Method of Contact (please specify)*							
	Cell Phone Alternate Phone							
4	Email							
	Language Preferred: Englis	h		Spanish			(please specify):	

	Prescriber Last Name* : Pre	escriber First Name	*:				
INFORMATION	Prescriber Office/Site/Clinic*						
ORN	Prescriber Phone Number*		Prescriber Fax Number*				
	Street Address*						
IBER	City*	State*	Zip Code*				
PRESCRIBER	NPI Number*						
PRE	Office Contact Name						
	Office Contact Phone Number with extension C		Office Email Address				

	Please attach a copy of the prescription	insurance benefit card, front and back	ι, or complete the following*			
	Prescription insurance benefit card attached. Patient do		pes not have insurance. Pa	atient requires co-pay only.		
VTION	Primary Insurance Company Name*		Secondary Insurance Company Name			
INFORMATION	Primary Insurance Company Phone Number*		Secondary Insurance Company Phone Number			
_	Name of Primary Cardholder*		Name of Primary Cardholder			
INSURANCE	Primary Insurance Member ID*	Group ID*	Secondary Insurance Member ID	Group ID		
NSUR	BIN*	PCN*	BIN	PCN		
-	Prior Authorization Status					
	Submitted	Not submitted	Approved	Denied		

Pat	ient	Full	Name:
-----	------	------	-------

Destant Allowitz sky								
Patient Allergies*: None Known	Known (please list kn	own allergies):						
Most recent Treatr	nent:							
None	BRAND Gilenya	GENERIC Fingolimod	Any oth	her DMT				
Initiating Therapy								
				ervation at initiation may be switche				
daily dose without	a need to repeat a First Do	se Observation (unless the previo	ous treatment was dis	scontinued more than 14 days prior)				
		ient, Baseline Assessments and a ion Information section on the ne		on are not required. (Please leave th	e rest of the Clinical Inform			
Baseline assessme	<u>ents</u>							
l am requestir	sting that Cycle Vita™ perform the following Baseline Assessments:							
CBC	LFTs and Bilirubin	VZV Antibody Serology	ECG Mad	cular Edema Screening				
Yes	No	setting up an FDO (First Dose Ob	servation)?					
First Dose Observa	<u>itions</u>							
	iantan Daaki							
				one tablet taken by mouth once a d				
			CENSO ODT 0.5 mg, o	one tablet taken by mouth once a da	у			
Body weight ≤ 4 Body weight ≥ 4								
Body weight ≤ 4 Body weight ≥ 4	40 kg (88.2 lbs): Dispense tructions (please specify):	·						
Body weight ≤ 4 Body weight ≥ 4 Alternative Inst TASCENSO ODT St	tructions (please specify): arter Pack Shipping Addre	255:	will be sent to the pat	tient's address.				
Body weight < 4 Body weight < 4 Alternative Inst TASCENSO ODT St The Starter Pack is	tructions (please specify): arter Pack Shipping Addre s always sent to the FDO a		will be sent to the pat	tient's address.	_			
Body weight < 4 Body weight < 4 Alternative Inst TASCENSO ODT St The Starter Pack is FDO to be perform	tructions (please specify): arter Pack Shipping Addre s always sent to the FDO a ed:	255:	will be sent to the pat	tient's address.				
Body weight < 4 Body weight < 4 Alternative Inst TASCENSO ODT St The Starter Pack is	tructions (please specify): arter Pack Shipping Addre s always sent to the FDO a ed:	255:	will be sent to the par	tient's address.	_			
Body weight < 4 Body weight < 4 Alternative Inst TASCENSO ODT St The Starter Pack is FDO to be perform In-home by Cyc	tructions (please specify): arter Pack Shipping Addre s always sent to the FDO a ed:	255:	will be sent to the par	tient's address.				

Take one 0.25 mg TASCENSO ODT tablet by mouth once a day with or without food, for a total dose of 0.25 mg/day. Dispensing pharmacy to notify pushen initial shipment is schedule Take one 0.5 mg TASCENSO ODT tablet by mouth once a day with or without food, for a total dose of 0.5 mg/day. Dispensing pharmacy to notify pushen initial shipment is schedule Other (please specify):		Number of days' supply/prescription: 30 days 90 da	iys	Refill(s):	One (1) Year	6 months	3 months	
Only prescriptions filled with product NDC numbers listed above shall be eligible for Cycle Vita (Eligible Products). Patient Directions (check all that apply): Take one 0.25 mg TASCENSO ODT tablet by mouth once a day with or without food, for a total dose of 0.25 mg/day. Take one 0.5 mg TASCENSO ODT tablet by mouth once a day with or without food, for a total dose of 0.5 mg/day. Shipping Instructions (check if appl Dispensing pharmacy to notify p when initial shipment is schedul Take one 0.5 mg TASCENSO ODT tablet by mouth once a day with or without food, for a total dose of 0.5 mg/day. Dispensing pharmacy to notify p when initial shipment is schedul While Cycle Vita secures appropriate benefit verification and authorization. Bridge may also be requested for existing patients who are temporarily experiencing in therapy due to insurance coverage. By checking the box above for Bridge, I, as the prescriber, with my signature below on this form, agree and attest that I will not submit a claim to or seek paymen patient or any third-party payer (c.g., Medicaid, Medicare, private insurance, etc.) for payment/reimbursement for any free product(s) provided by Cycle Vita. I a understand that any free product(c) eV Vita a reserves the right to modify or terminate the program without notice at any time. * Bridge is at no cost, for eligible patients within labeled indication only, and not contingent on purchase of any kind. Bridge is intended to support continuation or prescriber inform, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescribing, state prescriber inform, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescribing, state prescriber information on their pay due to	NO	TASCENSO ODT, 0.25 mg			NDC Number: 70709-062-30			
patient or any third-party payer (e.g., Medicaid, Medicare, private insurance, etc.) for payment/reimbursement for any free product(s) provided by Cycle Vita. I a understand that any free product provided by Cycle Vita may not be sold, traded, bartered, transferred, or returned for credit and will only be used for the patient above on this form. Cycle Vita reserves the right to modify or terminate the program without notice at any time. ⁺ Bridge is at no cost, for eligible patients within labeled indication only, and not contingent on purchase of any kind. Bridge is intended to support continuation of prescribed therapy if there is any disruption in therapy due to insurance coverage. Prescriber Declaration: I understand and agree that, as the prescriber, I will comply with my state-specific prescription requirements such as e-prescribing, state prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed TASCENSO ODT based		TASCENSO ODT, 0.5 mg			NDC Number: 70709-065-30			
patient or any third-party payer (e.g., Medicaid, Medicare, private insurance, etc.) for payment/reimbursement for any free product(s) provided by Cycle Vita. I a understand that any free product provided by Cycle Vita may not be sold, traded, bartered, transferred, or returned for credit and will only be used for the patient above on this form. Cycle Vita reserves the right to modify or terminate the program without notice at any time. ⁺ Bridge is at no cost, for eligible patients within labeled indication only, and not contingent on purchase of any kind. Bridge is intended to support continuation of prescribed therapy if there is any disruption in therapy due to insurance coverage. Prescriber Declaration: I understand and agree that, as the prescriber, I will comply with my state-specific prescription requirements such as e-prescribing, state prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed TASCENSO ODT based		Only prescriptions filled with product NDC numbers listed above shall be eligible for Cycle Vita (Eligible Products).						
patient or any third-party payer (e.g., Medicaid, Medicare, private insurance, etc.) for payment/reimbursement for any free product(s) provided by Cycle Vita. I a understand that any free product provided by Cycle Vita may not be sold, traded, bartered, transferred, or returned for credit and will only be used for the patient above on this form. Cycle Vita reserves the right to modify or terminate the program without notice at any time. ⁺ Bridge is at no cost, for eligible patients within labeled indication only, and not contingent on purchase of any kind. Bridge is intended to support continuation of prescribed therapy if there is any disruption in therapy due to insurance coverage. Prescriber Declaration: I understand and agree that, as the prescriber, I will comply with my state-specific prescription requirements such as e-prescribing, state prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed TASCENSO ODT based	IATI	Patient Directions (check all that apply):	Shipping Instructions (check if applicable):					
patient or any third-party payer (e.g., Medicaid, Medicare, private insurance, etc.) for payment/reimbursement for any free product(s) provided by Cycle Vita. I a understand that any free product provided by Cycle Vita may not be sold, traded, bartered, transferred, or returned for credit and will only be used for the patient above on this form. Cycle Vita reserves the right to modify or terminate the program without notice at any time. ⁺ Bridge is at no cost, for eligible patients within labeled indication only, and not contingent on purchase of any kind. Bridge is intended to support continuation of prescribed therapy if there is any disruption in therapy due to insurance coverage. Prescriber Declaration: I understand and agree that, as the prescriber, I will comply with my state-specific prescription requirements such as e-prescribing, state prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed TASCENSO ODT based	RN	Take one 0.25 mg TASCENSO ODT tablet by mouth once a da						
patient or any third-party payer (e.g., Medicaid, Medicare, private insurance, etc.) for payment/reimbursement for any free product(s) provided by Cycle Vita. I a understand that any free product provided by Cycle Vita may not be sold, traded, bartered, transferred, or returned for credit and will only be used for the patient above on this form. Cycle Vita reserves the right to modify or terminate the program without notice at any time. ⁺ Bridge is at no cost, for eligible patients within labeled indication only, and not contingent on purchase of any kind. Bridge is intended to support continuation of prescribed therapy if there is any disruption in therapy due to insurance coverage. Prescriber Declaration: I understand and agree that, as the prescriber, I will comply with my state-specific prescription requirements such as e-prescribing, state prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed TASCENSO ODT based	NFC	Take one 0.5 mg TASCENSO ODT tablet by mouth once a day	y with or without food, for a to	tal dose of 0.5	<i>mg/</i> day.	when initial simplifient is	sencuarca.	
patient or any third-party payer (e.g., Medicaid, Medicare, private insurance, etc.) for payment/reimbursement for any free product(s) provided by Cycle Vita. I a understand that any free product provided by Cycle Vita may not be sold, traded, bartered, transferred, or returned for credit and will only be used for the patient above on this form. Cycle Vita reserves the right to modify or terminate the program without notice at any time. ⁺ Bridge is at no cost, for eligible patients within labeled indication only, and not contingent on purchase of any kind. Bridge is intended to support continuation of prescribed therapy if there is any disruption in therapy due to insurance coverage. Prescriber Declaration: I understand and agree that, as the prescriber, I will comply with my state-specific prescription requirements such as e-prescribing, state prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed TASCENSO ODT based	II NO	Other (please specify):						
patient or any third-party payer (e.g., Medicaid, Medicare, private insurance, etc.) for payment/reimbursement for any free product(s) provided by Cycle Vita. I a understand that any free product provided by Cycle Vita may not be sold, traded, bartered, transferred, or returned for credit and will only be used for the patient above on this form. Cycle Vita reserves the right to modify or terminate the program without notice at any time. ⁺ Bridge is at no cost, for eligible patients within labeled indication only, and not contingent on purchase of any kind. Bridge is intended to support continuation of prescribed therapy if there is any disruption in therapy due to insurance coverage. Prescriber Declaration: I understand and agree that, as the prescriber, I will comply with my state-specific prescription requirements such as e-prescribing, state prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed TASCENSO ODT based	SCRIPTIC	Bridge ⁺ - "Bridge" is a FREE supply of TASCENSO ODT that allows patients already on a fingolimod product, with an urgent medical need to begin therapy immediately while Cycle Vita secures appropriate benefit verification and authorization. Bridge may also be requested for existing patients who are temporarily experiencing disruption in therapy due to insurance coverage.						
prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient a prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed TASCENSO ODT based	PRE	* Bridge is at no cost, for eligible patients within labeled indication only, and not contingent on purchase of any kind. Bridge is intended to support continuation of						
prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient a prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed TASCENSO ODT based								
	SURIBER LARATION	Prescriber Declaration: I understand and agree that, as the prescriber, I will comply with my state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient and prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed TASCENSO ODT based on my professional judgment of medical necessity. I authorize Cycle Vita, its affiliates, agents, and contractors (collectively, "Cycle Vita" to act on my behalf for the limited purposes of transmitting this prescription to the appropriate pharmacy designated by the above-named patient utilizing their benefit plan. I authorize Cycle Vita, its affiliates, agents and contractors to perform any steps necessary to secure reimbursement for TASCENSO DDT, including but not limited to insurance verification and case assessment. I understand that Cycle Vita may need additional information, and I agree to provide it as needed for the purposes of securing reimbursement.						
	DEC							
		X				Data of Oliverations		
Prescriber Signature Date of Signature Dispense as Written (Substitution Permitted) (MM/DD/YYYY)		-	(Substitution Permitted)					